Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

Francesconi, Alessandra; Dupre, Simon; Matos, Marco; Martin, David; Hughes, Brett; Wyld, David; Lickliter, Jason D.

doi:10.1016/j.jocn.2009.12.009

Cited by 54 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nitrourea, TMZ, and bevacizumab (BVZ), alone or in combination, have been used to treat patients with recurrent HGG [16][17][18]. Additionally, BVZ combined with irinotecan resulted in 6-month PFS and OS rates of 46% and 77%, respectively [19,20].…”

Section: Discussionmentioning

confidence: 99%

“…If patients displayed symptoms indicating tumor progression, an evaluation including imaging was performed. The diagnosis of tumor recurrence was based on changes in the tumor volume detected using dynamic contrast-enhanced MRI, and additionally considering the standardized uptake value (SUV) on 18 flurodeoxyglucosepositron emission tomography [12]. The failure pattern was defined as "in field" if more than 80% of the recurrent tumor was inside the initial planning target volume (PTV); it was considered "marginal" if 20% to 80% of the lesion was inside the previous PTV [13].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas

Heo¹,

Kim²,

Oh³

et al. 2017

neo

View full text Add to dashboard Cite

Salvage therapy for recurrent high grade gliomas (HGG) includes surgery, radiotherapy and chemotherapy, however, standard treatment does not exist. We evaluated the tolerability and efficacy of re-irradiation (re-RT) with hyperthermia (HT) for patients with recurrent HGG. From September 2010 to July 2015, 20 patients with recurrent HGG were treated with re-RT and HT. The radiotherapy dose of 30 Gray (Gy) was delivered with 2 Gy per fraction daily, and HT was performed twice weekly. Primary endpoints were treatment compliance and toxicity. Second endpoints were overall survival (OS) and progression free survival (PFS). The median interval between initial RT and re-RT was 11 months. During re-RT with HT, there were no significant acute morbidities over grade 3. Median overall survival (OS) from re-irradiation was 8.4 months and the 6 and 12 months survival rate were 67% and 30%, respectively. The median progression free survival (PFS) from re-irradiation was 4.1 month. Our findings suggested that concurrent re-RT with HT was a safe and well-tolerated. In addition, the combination re-RT and HT could be a valuable salvage treatment option for selected recurrent HGG patients with poor performance status.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas

Heo¹,

Kim²,

Oh³

et al. 2017

neo

View full text Add to dashboard Cite

show abstract

“…27,28,32,[38][39][40][41][42][43][44][45][46][47] In addition, several retrospective studies have also been reported combining bevacizumab and irinotecan; carboplatin; carboplatin and cetuximab; carboplatin, etoposide, and ifosfamide; lomustine; carmustine; etoposide; or temozolomide. [48][49][50][51][52][53][54][55][56][57][58] Although these small studies are not easily compared due to their size and various patient populations, the consensus to date has been that no combination significantly surpasses the outcomes of bevacizumab monotherapy for recurrent glioma. 9 …”

Section: Early Study Of Bevacizumab In Patients With Recurrent Glioblmentioning

confidence: 99%

Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

Field

Jordan

Wen

et al. 2014

Cancer

View full text Add to dashboard Cite

Anti-angiogenic therapy for glioblastoma has been in the spotlight for several years, as researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. Bevacizumab in particular, in the second half of the last decade, became the most significant breakthrough in anti-glioblastoma therapy since temozolomide. Optimism for bevacizumab has been somewhat challenged given recent clinical trials that have raised questions regarding its clinical effectiveness, the optimal timing of its use and the validity of endpoints, among other issues. In addition, uncertainty has recently arisen regarding the effects of bevacizumab on quality of life and neurocognitive function, two key clinical endpoints of unquestionable significance among glioblastoma patients. In this review, we highlight these controversies and other recent work related to bevacizumab for glioblastoma. Cancer 2015;121:997

show abstract

“…Combination therapies utilizing an anti-VEGF platform studied in a prospective fashion include bevacizumab with the following agents: irinotecan (9,10), etoposide (12), erlotinib (13), temzolomide (14), carboplatin plus irinotecan (15) and carboplatin plus etoposide (16). The majority of combinations offered similar benefits but toxicity was generally more pronounced when cytotoxic regimens were added to anti-VEGF therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Carboplatin monotherapy has been shown to be modestly effective in therapy of recurrent malignant glioma (5,18). The results of combination therapies utilizing carboplatin for this indication have also been encouraging (16,19).…”

Section: Introductionmentioning

confidence: 99%

Carboplatin and bevacizumab for recurrent malignant glioma

et al. 2012

View full text Add to dashboard Cite

Abstract. Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy, the survival rate of this disease remains poor. The introduction of agents which disrupt the function of vascular endothelial growth factor (VEGF) and its receptors to glioma therapy has resulted in an unusually high percentage of patients experiencing radiographic responses. Bevacizumab, approved by the Food and Drug Administration for the treatment of recurrent glioblastoma in 2009, has changed the field of neuro-oncology. The drug has been utilized as a single agent and in combination with the classic cytotoxic agents typically applied in this setting. Numerous studies have reported high response rates and encouraging extensions of time-to-progression. The optimal schedule and combination of bevacizumab with alternative drugs has not been identified. The current study presents the results of a retrospective analysis of the combination therapy utilizing bevacizumab with the alkylating agent carboplatin in patients with recurrent malignant glioma.

show abstract

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

Cited by 54 publications

References 23 publications

Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas

Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas

Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

Carboplatin and bevacizumab for recurrent malignant glioma

Contact Info

Product

Resources

About